US-based biopharma, Actuate Therapeutics’s elraglusib reduced the risk of death by 37% in a Phase I/II metastatic pancreatic cancer trial. The randomised Phase I/II trial (NCT03678883 ...
Hosted on MSN5mon
InvestorNewsBreaks – Actuate Therapeutics, Inc. (NASDAQ: ACTU) Closes on $22.4M Initial Public OfferingActuate Therapeutics (NASDAQ: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, recently announced the ...
CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate” or the "Company”), a clinical-stage biopharmaceutical company focused on ...
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for ...
Financials are currently not available. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a biopharmaceutical company with a market capitalization of $161.72 million, announced today that the... ByInvesting.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback